8-K: Adicet Bio Reports Positive Prula-cel Data in Lupus

Adicet Bio announced positive safety and efficacy data from its Phase 1 study of prula-cel in patients with Systemic Lupus Erythematosus (SLE) with or without Lupus Nephritis (LN), showing high remission rates and a favorable safety profile.

Summary

• Adicet Bio has released positive preliminary data from its Phase 1 study of prula-cel (formerly ADI-001) for Systemic Lupus Erythematosus (SLE) with or without Lupus Nephritis (LN).
• The study evaluated 22 efficacy-evaluable patients, with follow-up ranging from 6 to 21 months.
• Key efficacy findings include a 50% complete renal response (CRR) rate at 12 months for lupus nephritis patients and a 54% DORIS remission rate at 12 months for all evaluable patients.
• All patients discontinued immunosuppressants, and all but one tapered background steroids to 5 mg or less of prednisone equivalent.
• The safety profile was generally well-tolerated, with no cytokine release syndrome (CRS) greater than Grade 2, no dose-limiting toxicities (DLTs), no immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), and no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS).
• The company plans to initiate start-up activities for a pivotal study in lupus nephritis in Q4 2026, with potential expansion to include lupus patients without nephritis.
• Biomarker data suggests an immune reset, with all patients achieving undetectable CD19+ B cells and subsequent nave-dominant B-cell reconstitution.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, indicating significant progress in a challenging autoimmune disease indication with promising efficacy and a favorable safety profile.

Positives

• High rates of immunosuppressant-free responses observed in a heavily pretreated patient population.
• 50% of evaluable lupus nephritis patients achieved a complete renal response (CRR) at 12 months.
• 54% of evaluable patients achieved DORIS remission at 12 months, with all 12-month responses ongoing.
• All patients discontinued immunosuppressants, and most tapered steroids significantly.
• Favorable safety profile with no CRS greater than Grade 2, no DLTs, no IEC-HS, and no ICANS.
• Evidence of immune reset shown through undetectable CD19+ B cells and B-cell reconstitution.
• FDA alignment for outpatient administration of prula-cel.
• Plans to initiate pivotal study start-up activities in Q4 2026, indicating progression towards regulatory approval.

Negatives

• While positive, the CRR rate of 50% and DORIS remission rate of 54% at 12 months, though promising, are from a small Phase 1 study and may not be fully predictive of larger pivotal trials.
• One patient with a UPCR of 0.65 g/g, while off immunosuppressants, did not maintain a complete response.
• Infections were reported in 54% of patients, with Grade 3 or higher in 8.3%, which is a common concern with immunotherapies.

Risks

• Positive results from a Phase 1 study may not be predictive of future or ongoing studies.
• Clinical studies may fail to demonstrate adequate safety and efficacy, potentially preventing or delaying regulatory approval.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable.
• The company's ability to execute its strategy, including obtaining regulatory approvals on expected timelines, is subject to risks.
• Global economic conditions and public health crises could disrupt studies, operations, and the ability to raise capital.

Future Outlook

The company plans to initiate pivotal study start-up activities for lupus nephritis in Q4 2026 and is discussing potential expansion to include lupus patients without nephritis with the FDA in Q4 2026. Clinical data updates are anticipated in the first half of 2027 for systemic sclerosis and mid-2027 for LN/SLE.

Management Comments

• "We observed complete renal responses and DORIS remissions after a single dose of prula-cel in patients who had failed multiple prior therapies. Notably, these remissions were achieved off immunosuppression and were accompanied by biological evidence of an immune reset."
• "In a disease where chronic therapy with limited efficacy and significant tolerability and safety considerations remains the standard of care, the prospect of durable, treatment-free remission after a single treatment could be transformative for individuals living with lupus."
• "Today's results mark an exciting step forward for Adicet and for lupus patients with or without nephritis. The data suggests prula-cel has the potential to offer lupus patients a highly differentiated treatment option: a single dose, off-the-shelf therapy, with a favorable safety profile, that may lead to immunosuppressant free remission."
• "Importantly, the compelling efficacy data observed to date has been accompanied by a generally favorable safety profile with no cases of IEC-HS, no ICANS and no CRS beyond Grade 2 reported in the study."
• "Combined with the FDA's support of outpatient administration of prula-cel, and the scalability of our off-the-shelf manufacturing, these findings support the potential of prula-cel to redefine the treatment expectations for patients living with systemic lupus erythematosus with or without lupus nephritis."

Industry Context

StockSavvy.ai notes that the development of off-the-shelf CAR-T therapies for autoimmune diseases represents a significant advancement, aiming to overcome the logistical and cost barriers associated with autologous CAR-T. The positive data for prula-cel in SLE/LN, particularly its favorable safety profile and potential for durable, immunosuppression-free remission, positions it as a potentially transformative therapy in a field with substantial unmet needs.

Comparison to Industry Standards

• Compared to autologous CAR-T therapies, prula-cel offers an off-the-shelf, allogeneic approach, eliminating the need for patient-specific leukapheresis and manufacturing, which is a significant logistical advantage.
• The observed 50% CRR and 54% DORIS remission rates at 12 months in a heavily pretreated population are competitive, especially considering the favorable safety profile (no IEC-HS, ICANS, or >Grade 2 CRS) compared to some autologous CAR-T therapies which can have higher rates of severe toxicities.
• Existing therapies for SLE/LN, such as belimumab and anifrolumab, are typically chronic treatments and have not demonstrated the same rates of complete remission or the potential for treatment-free remission as suggested by prula-cel's data.
• The safety profile of prula-cel, including its suitability for outpatient administration, contrasts with the intensive monitoring often required for other CAR-T therapies.

Stakeholder Impact

• Shareholders: Positive data and clear path to pivotal studies are likely to be viewed favorably, potentially increasing investor confidence.
• Patients: The potential for a single-dose, off-the-shelf therapy offering durable, immunosuppression-free remission with a favorable safety profile could significantly improve the quality of life and treatment outcomes for SLE and LN patients.
• Healthcare Providers: The prospect of an outpatient-administrable therapy with a manageable safety profile could simplify treatment protocols and expand access to advanced therapies.
• Regulators (FDA): Continued alignment with the FDA on the regulatory path for prula-cel, including the design of the pivotal study, is crucial for future approval.

Next Steps

• Initiate start-up activities for a pivotal study in lupus nephritis in the fourth quarter of 2026.
• Discuss potential expansion of the pivotal study to include lupus patients without nephritis with the FDA in the fourth quarter of 2026.
• Provide an anticipated clinical data update in systemic sclerosis (SSc) in the first half of 2027.
• Provide an anticipated clinical data update in LN/SLE in mid-2027.

Key Dates

Recommendation

The filing presents highly encouraging Phase 1 data for prula-cel in SLE/LN, demonstrating significant efficacy with a favorable safety profile and a clear path towards a pivotal study. The potential for a transformative, off-the-shelf CAR-T therapy for a significant unmet medical need warrants a strong buy recommendation.

Keywords

Prula-cel, Systemic Lupus Erythematosus, Lupus Nephritis, CAR-T therapy, Autoimmune disease, Clinical trial, B-cell depletion, Immunosuppression